His work includes developing non-covalent, selective inhibitors designed to work against multiple emerging coronavirus strains, including MERS-CoV.

He specializes in determining high-resolution 3D structures of enzymes (such as 3CLpro and PLpro) in coronaviruses and cancer to design selective drugs.

He is the Robert Wallace Miller Director of the Purdue Institute for Cancer Research , where he leads efforts in developing novel cancer therapies, diagnostics, and targeting cancer at the cellular level.

), helping guide the development of treatments like .

He is involved in translational research to turn basic molecular findings into commercial drugs for cancer and Alzheimer's disease.

Dr. Andrew Mesecar is a prominent researcher specializing in biochemistry, structural biology, and cancer drug discovery. His key research features and contributions include: